Arbutus Biopharma Corp ABUS

Healthcare Biotechnology

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.

NDAQ:ABUS - Post by User

Arbutus Biopharma Corp

Bullboard Posts

Comment by HARLEYDAVIDSON21on Sep 08, 2014 2:29pm

168 Views

Post# 22916449

RE:tekmira

shade1 wrote: with buy out rumors flying any ideas as to who would have the most interest to compliment there own technologies

Tekmira is capitalised at a measly £400m and would cost a bidder in the region of £1bn-plus, a relatively small mouthful for any cash-rich giant.

Rumours suggest two of the interested parties could be the UK’s Shire (22p off at 4894p) and GlaxoSmithKline (15.5p dearer at 1463p.

The mega premium paid for InterMune puts a valuation of $40 plus a-share on Tekmira.

All just rumour though at this point..........as I would love to see $40 a share right now,I'd just as soon see TKM continue on their own pace. :)

Bullboard Posts

Level up your trading with BMO InvestorLine’s enhanced features